"No-profit" clinical study for the improvement of clinical practice, to evaluate the efficacy of anakinra in reducing the glycated haemoglobin in patients affected by rheumatoid arthritis and diabetes; randomized, open label, parallel group, controlled clinical study.
Phase of Trial: Phase IV
Latest Information Update: 18 Dec 2018
Price : $35 *
At a glance
- Drugs Anakinra (Primary)
- Indications Rheumatoid arthritis; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 12 Dec 2018 Status changed from recruiting to discontinued.
- 16 Jun 2014 New trial record